BLB(SZ:002286)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 was ¥683,432,321.50, representing a decrease of 2.06% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2023 was ¥13,228,855.13, down 33.27% year-on-year, while the year-to-date net profit was ¥45,988,089.59, a decline of 58.41%[7]. - The basic earnings per share for Q3 2023 was ¥0.04, reflecting a 20.00% decrease compared to the same period last year[7]. - Total operating revenue for Q3 2023 was CNY 1,965,015,829.72, a decrease of 5.5% compared to CNY 2,080,619,133.17 in the same period last year[19]. - Net profit for Q3 2023 was CNY 45,988,089.59, down 58.4% from CNY 110,577,810.94 in Q3 2022[20]. - The total comprehensive income for the third quarter was CNY 23,776,804.39, a decrease from CNY 93,668,081.58 in the previous year[21]. - Basic and diluted earnings per share for the quarter were both CNY 0.12, down from CNY 0.24 year-over-year[21]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,758,376,450.70, down 8.24% from the end of the previous year[7]. - The company's total assets decreased to CNY 2,758,376,450.70 from CNY 3,006,135,458.00, reflecting a reduction in asset base[18]. - Total liabilities decreased to CNY 755,832,688.26 from CNY 1,001,792,603.74, indicating improved liability management[18]. - The total current assets decreased from ¥995,776,570.43 to ¥852,056,198.54, a decline of about 14.4%[16]. - The total equity attributable to shareholders decreased to CNY 2,002,543,762.44 from CNY 2,004,342,854.26, reflecting a decline in shareholder value[18]. Cash Flow - The company reported a net cash flow from operating activities of ¥204,388,953.01, an increase of 74.15% year-to-date[10]. - Cash flow from operating activities generated a net amount of CNY 204,388,953.01, compared to CNY 117,365,682.75 in the same period last year, representing an increase of approximately 74.2%[22]. - Cash inflow from operating activities totaled CNY 2,198,161,583.67, down from CNY 2,463,086,783.06, indicating a decrease of about 10.7%[22]. - Cash outflow from operating activities was CNY 1,993,772,630.66, compared to CNY 2,345,721,100.31, reflecting a decrease of approximately 15.0%[22]. - The net cash flow from investing activities was -CNY 120,441,575.69, an improvement from -CNY 195,394,525.59 in the previous year[24]. - Cash flow from financing activities resulted in a net outflow of -CNY 186,401,920.52, compared to a net inflow of CNY 99,503,916.03 in the same period last year[24]. - The ending balance of cash and cash equivalents was CNY 274,954,138.81, down from CNY 439,043,349.51 year-over-year[24]. - The company received CNY 199,680,000.00 from borrowings during the quarter, a decrease from CNY 463,900,000.00 in the previous year[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,077[13]. - The top shareholder, Beijing Yongyu Investment Management Co., Ltd., holds 12.75% of shares, totaling 47,273,390 shares, with 8,000,000 shares frozen[13]. - The number of preferred shareholders with voting rights is zero[13]. - The company has not disclosed any related party relationships among the top shareholders[13]. Operational Strategy - The company plans to expand the application of erythritol in health products and pharmaceuticals while introducing new products to accelerate industrialization[4]. - The company faced challenges due to insufficient terminal consumption and inventory reduction pressures from downstream enterprises, but it remains optimistic about the long-term potential in the low-sugar and sugar substitute markets[4]. - The company will enhance its international business to broaden its market reach[4]. - The company is focusing on improving operational efficiency and cost management strategies to navigate the current market challenges[19]. Financial Management - The financial expenses increased by 212.89% year-to-date, primarily due to increased foreign exchange losses[10]. - The company reported a significant decrease in long-term borrowings by 87.61% due to early repayment of loans[10]. - Research and development expenses for Q3 2023 were CNY 6,464,413.31, slightly down from CNY 6,694,335.48, indicating a focus on cost management in R&D[19]. - The company has not engaged in any financing or securities lending activities for its stock[13]. - The company did not conduct an audit for the third quarter report[25].